Mirum Pharmaceuticals, Inc.

MIRM · Nasdaq · United States

Share price · MIRM

$92.49-8.38 (-8.31%) 3M

close as of 2026-11-18 · 24h delayed · vol 498K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MIRM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+11.4%
  2. 18 Sep 2026-7.1%

    Nothing announced by MIRM that day or the session before.

  3. 6 Aug 2026-11.0%
  4. 30 Jun 2026-4.8%

    Nothing announced by MIRM that day or the session before.

  5. 4 May 2026+9.6%
  6. 26 Feb 2026-15.1%
  7. 9 Jan 2026+6.1%

    Nothing announced by MIRM that day or the session before.

  8. 19 Dec 2025+10.6%
  9. 17 Dec 2025+2.9%

    Nothing announced by MIRM that day or the session before.

  10. 16 Dec 2025+4.6%

    Nothing announced by MIRM that day or the session before.

Share of unusual movement by asset

For each asset, the share of MIRM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
maralixibat (Livmarli)
events and moves
2shown from 8 days
volixibat
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—31%
Sessions with no dated event—67%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
maralixibat(Livmarli)
Approved
Ileal bile acid transporter (IBAT)Small molecule
Alagille Syndrome
Phase 2
Ileal bile acid transporter (IBAT)Small molecule
Primary Sclerosing CholangitisCholestatic Liver Disease
Primary Biliary Cholangitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
volixibatPhase 2Primary Biliary Cholangitis, PBC
Est. primary completion 2027-01 · NCT05050136 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
maralixibat · LivmarliPhase 2Intrahepatic Cholestasis of Pregnancy
Est. primary completion 2029-01-12 · NCT07823127 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 October 2026Topline resultmaralixibatEXPAND Phase 3 topline: primary endpoint met
Mirum Pharmaceuticals, Inc. · Source ↗
4 May 2026Topline resultvolixibatVISTAS Phase 2b met primary endpoint in PSC
Mirum Pharmaceuticals, Inc. · Source ↗
December 2023Topline resultmaralixibatPhase 2b EMBARK in biliary atresia did not meet its primary or key secondary endpoints

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$186M$108M$243M+ $131M short-term inv.$41M-$4.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$176M$91M$331M+ $108M short-term inv.$67M-$44M operating cash flowreport ↗
2026-Q1$160M$98M$325M+ $61M short-term inv.$790M-$229M operating cash flowreport ↗
2025-Q3$133M$43M$282M+ $94M short-term inv.—$40M operating cash flowreport ↗
2025-Q2$128M$46M$228M+ $76M short-term inv.$5.9M$12M operating cash flowreport ↗
2025-Q1$112M$46M$212M+ $66M short-term inv.$15M-$2.0M operating cash flowreport ↗
2024-Q3$90M$32M$223M+ $61M short-term inv.$14M$4.0M operating cash flowreport ↗
2024-Q2$78M$33M$233M+ $45M short-term inv.$25M-$3.8M operating cash flowreport ↗
2024-Q1$69M$32M$303M$25M$15M operating cash flowreport ↗
2023-Q3$48M$26M$303M+ $3.0M short-term inv.$24M-$18M operating cash flowreport ↗
2023-Q2$38M$22M$297M+ $33M short-term inv.$74M-$2.3M operating cash flowreport ↗
2023-Q1$32M$24M$49M+ $83M short-term inv.$30M-$34M operating cash flowreport ↗
2022-Q3$19M$26M$36M+ $150M short-term inv.$36M-$26M operating cash flowreport ↗
2022-Q2$17M$25M$55M+ $70M short-term inv.$27M-$20M operating cash flowreport ↗
2022-Q1$13M$24M$46M+ $94M short-term inv.$37M-$40M operating cash flowreport ↗
2021-Q3$5.0M$30M$56M+ $134M short-term inv.$47M-$34M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$521M$186M$297M+ $87M short-term inv.$5.8M$56M operating cash flowreport ↗

Mirum Pharmaceuticals reported FY2025 revenue of $521.31M, up 54.7% YoY, with R&D spend of $186.18M, up 32.4% YoY. Cash and equivalents were $296.68M, and the company reported a net loss of $23.36M, with a quarterly net burn of $23.36M.

Business highlights include the February 2025 FDA approval of Ctexli for adults with cerebrotendinous xanthomatosis. The company expects topline data from the EXPAND Phase 3 study in Q4 2026 and from the volixibat VISTAS Phase 2b study in Q2 2026, with VANTAGE enrollment expected to complete in H2 2026. After completing the Bluejay Therapeutics acquisition on January 23, 2026, brelovitug is advancing in the AZURE program, with AZURE-1 and -4 topline results expected in H2 2026, while the MRM-3379 BLOOM Phase 2 study expects data in 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$337M$141M$223M+ $58M short-term inv.$22M$10M operating cash flowreport ↗
2023-FY$186M$103M$286M+ $0 short-term inv.$41M-$71M operating cash flowreport ↗
2022-FY$77M$107M$28M+ $124M short-term inv.$34M-$120M operating cash flowreport ↗
2021-FY$19M$131M$31M+ $125M short-term inv.$21M-$133M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($9.0M), 63 sales ($45.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Ramasastry Saira · directorOption exercise2,000$28.97$58KForm 4
2026-11-16Ramasastry Saira · directorOpen-market sale2,000$92.28$185KForm 4
2026-11-16Ramasastry Saira · directorOption exercise (derivative)2,000——Form 4
2026-11-11Brege Laura · directorOption exercise14,167$16.71$237KForm 4
2026-11-11Brege Laura · directorOpen-market sale10,907$94.05$1.0MForm 4
2026-11-11Brege Laura · directorOpen-market sale3,260$94.74$309KForm 4
2026-11-11Brege Laura · directorOption exercise (derivative)14,167——Form 4
2026-11-04Peetz Christopher · director, CHIEF EXECUTIVE OFFICEROption exercise20,000$2.94$59KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 309 reporting institutions held 68.2M shares ($6.1B, 104.5% of shares outstanding).

#InstitutionSharesValue
1Frazier Life Sciences Management, L.P.7,679,684$709.4M
2JANUS HENDERSON GROUP PLC6,945,813$641.8M
3BlackRock, Inc.3,846,530$355.3M
4VANGUARD CAPITAL MANAGEMENT LLC2,414,776$223.1M
5FMR LLC1,965,375$181.6M
6STATE STREET CORP1,944,281$179.6M
7BVF INC/IL1,584,727$146.4M
8VANGUARD PORTFOLIO MANAGEMENT LLC1,432,083$132.3M
9EVENTIDE ASSET MANAGEMENT, LLC1,408,871$130.1M
10WELLINGTON MANAGEMENT GROUP LLP1,334,809$123.3M
11NOVO HOLDINGS A/S1,325,000$122.4M
12GEODE CAPITAL MANAGEMENT, LLC1,260,003$116.4M
13TANG CAPITAL MANAGEMENT LLC1,236,027$114.2M
14TCG Crossover Management, LLC1,062,049$98.1M
15CITADEL ADVISORS LLC1,052,048$97.2M